Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre,
Wynne Wijaya1, Thomas Morris2, Martin D Forster3
1Department of Oncology, University of Oxford, Oxford, Oxfordshire, UK.
Background:
Survivin, an inhibitor of apoptosis protein (IAP), is highly expressed in various cancers but has weak immunogenicity as a self-derived tumour-associated antigen (TAA). OVM-200, a survivin recombinant overlapping peptide (ROP) vaccine, consists of overlapping peptides linked by the target sequence (LRMK) for cathepsin S, preserving T-cell and most antibody epitopes. OVM-200 elicits both cellular and humoral immune responses against survivin-expressing cancer cells. This phase 1a, multicentre, open-label trial (OVM-200-100) evaluates OVM-200 as a therapeutic vaccine in patients with non-small cell lung, ovarian, and prostate cancer. This Phase 1 trial is also the first time the ROP technology platform has been used in human trials.
Methods:
Twelve eligible patients received three subcutaneous OVM-200 doses at 2-week intervals using a 3 + 3 dose-escalation design. Four dose levels (250, 500, 1000, and 2000 μg) were tested to determine the optimal dose for phase 1b. The primary endpoint was safety and tolerability, while secondary endpoints included immunogenicity (antibody and T-cell response) and tumour response (RECIST criteria). This trial was registered with ClinicalTrials.gov (NCT05104515) and EudraCT (2021-001545-12) and took place from 28/09/2021 to 04/05/2023.
Findings:
OVM-200 was well tolerated, with no serious adverse drug reactions (ADRs) or dose-limiting toxicities (DLTs). All adverse events were Grade 1 injection site reactions (ISRs). The 2000 μg dose group achieved the highest median anti-survivin IgG titre (1:327,680) at the end of the study (EOS) and a median ELISpot T cell response of 1282 SFU per million cells on day 22. Disease stabilisation (SD) was observed in 6 of 12 patients (50%), including all 3 patients (100%) in the 2000 μg group, some of which were stabilisations of limited duration. Based on these findings, the 2000 μg dose was selected for further evaluation in phase 1b.
Interpretation:
OVM-200 is well tolerated and induces a robust humoral response, with a considerable cellular response and preliminary evidence of disease stabilisation. Phase 1b is ongoing to further evaluate its safety and efficacy at the selected dose.
Funding:
Oxford Vacmedix UK Ltd.
Insights
The survivin recombinant overlapping peptide (ROP) vaccine, OVM-200, is well-tolerated in cancer patients. This therapeutic vaccine shows promising immune responses and disease stabilization, warranting further investigation.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Survivin, a highly expressed cancer antigen, has low immunogenicity.
- OVM-200 is a novel survivin recombinant overlapping peptide (ROP) vaccine designed to elicit immune responses.
- This Phase 1a trial is the first human study of the ROP technology platform.
Purpose of the Study:
- Evaluate the safety and tolerability of OVM-200 in patients with non-small cell lung, ovarian, and prostate cancer.
- Determine the optimal dose for OVM-200 in Phase 1b trials.
- Assess the immunogenicity and preliminary anti-tumour activity of OVM-200.
Main Methods:
- A multicentre, open-label, dose-escalation Phase 1a trial (OVM-200-100).
- Twelve patients received three subcutaneous doses of OVM-200 at escalating doses (250-2000 μg).
- Primary endpoint: safety and tolerability; Secondary endpoints: immunogenicity and tumour response (RECIST).
Main Results:
- OVM-200 was well tolerated with no serious adverse drug reactions or dose-limiting toxicities.
- The 2000 μg dose showed the highest median anti-survivin IgG titre (1:327,680) and T-cell response (1282 SFU/million).
- Disease stabilization was observed in 50% of patients (100% in the 2000 μg group).
Conclusions:
- OVM-200 is a safe and well-tolerated therapeutic vaccine candidate.
- OVM-200 induces robust humoral and cellular immune responses against survivin.
- Preliminary disease stabilization supports further evaluation in Phase 1b trials.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...